Access cutting-edge inflammatory bowel disease (crohn's disease and ulcerative colitis) treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Seattle location
Preparing your pre-screening questions…
Access inflammatory bowel disease (crohn's disease and ulcerative colitis) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related inflammatory bowel disease (crohn's disease and ulcerative colitis) treatment provided free
Check if you qualify for this inflammatory bowel disease (crohn's disease and ulcerative colitis) clinical trial in Seattle, WA
No-Cost Study Care
Local to Seattle
Convenient for WA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Brief Summary The aim of the FIBER study is to identify potential triggers associated with the later development of IBD (inflammatory bowel disease) based on baseline characteristics and biosamples (blood, urine, stool, saliva, and tissue). Aim 1: To identify clinical, demographic, and immunologic factors associated with an increased risk of developing IBD in family members of IBD patients. This aim will investigate the role of clinical factors (e.g., age of onset, gender, and family history), demographic factors (e.g., socioeconomic status, geographical location), and immune system markers (e.g., inflammatory cytokine profiles, immune cell populations) in predicting the likelihood of family members developing IBD over time. Aim 2: To examine dietary, environmental, and immunologic influences on the development of IBD in family members of IBD patients. This aim will explore how dietary habits (e.g., fiber, fats, processed foods), environmental exposures (e.g., smoking, pollution, and antibiotic use), and immune responses (e.g., changes in T-cell activation, inflammatory markers) contribute to the risk of IBD in family members. Aim 3: To analyze the multi-omic (metagenomic, transcriptomic, proteomic) cellular signatures of host and microbial signatures in family members of IBD patients and their association with IBD onset. This aim will investigate changes in the gut microbiome and immune-related gene expression profiles (transcriptomics) in family members. Specifically, the aim will focus on how shifts in microbial composition and host immune response genes (e.g., those involved in inflammation and epithelial barrier function) correlate with an increased risk of IBD development. Aim 4: To investigate the multi-omic (metabolomic, transcriptomic, proteomic) cellular signature of host and microbial signatures in family members to identify biomarkers predictive of IBD development. This aim will involve examining the metabolic, protein, and transcriptomic signatures (e.g., circulating cytokines, immune receptor expression) in blood, urine, or stool samples. The study will seek to identify early biomarkers from these profiles that can predict the onset of IBD, even in asymptomatic family members.
Sponsor: Seattle Children's Hospital
Yes, this clinical trial (NCT07791862) has an active research site in Seattle, WA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for inflammatory bowel disease (crohn's disease and ulcerative colitis) treatment options in Seattle, WA, this clinical trial (NCT07791862) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced inflammatory bowel disease (crohn's disease and ulcerative colitis) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all inflammatory bowel disease (crohn's disease and ulcerative colitis) clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Seattle — not just this study.
Browse Multiple Myeloma Trials in Seattle →